Articles related to CLINICAL TRIALS

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.

In a recent clinical trial, thrombectomy combined with medical care was shown to significantly improve functional outcomes in patients with large acute strokes, reducing mortality rates to 36.1% compared to 55.5% in those receiving only medical care.

In a recent study, 91% of patients with transfusion-dependent β-thalassemia achieved independence from transfusions following treatment with Exagamglogene Autotemcel.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

This phase 2 study underscores the challenges in enhancing therapeutic outcomes in metastatic castration-resistant prostate cancer with AZD4635 combined with immunotherapy, indicating a minimal PSA response among treated patients.

In the recent phase 3 trial, recombinant ADAMTS13 demonstrated a profound capability to maintain ADAMTS13 activity at approximately 100% of normal levels, highlighting its potential to substantially reduce thrombotic complications in patients with congenital TTP.